Compare RAND & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RAND | TXMD |
|---|---|---|
| Founded | 1969 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.7M | 25.9M |
| IPO Year | N/A | N/A |
| Metric | RAND | TXMD |
|---|---|---|
| Price | $11.06 | $2.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.8K | ★ 98.0K |
| Earning Date | 03-09-2026 | 03-26-2026 |
| Dividend Yield | ★ 10.49% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.03 |
| Revenue | ★ $7,327,287.00 | $2,796,000.00 |
| Revenue This Year | N/A | $427.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $90.45 |
| Revenue Growth | N/A | ★ 75.19 |
| 52 Week Low | $10.05 | $0.72 |
| 52 Week High | $31.89 | $2.95 |
| Indicator | RAND | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.60 | 56.98 |
| Support Level | $10.48 | $2.12 |
| Resistance Level | $11.15 | $2.45 |
| Average True Range (ATR) | 0.34 | 0.23 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 67.14 | 39.08 |
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.